BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio Pharmaceuticals has maintained its 'Strong Buy' rating following the release of additional data from its Encaleret ADH1 clinical trial. The company also expects three FDA reviews in the coming months, which could potentially expand its product pipeline.

The new data showed that Encaleret, an investigational therapy for the treatment of autosomal dominant hypocalcemia (ADH1), met its primary and secondary endpoints in a Phase 2b trial. The FDA reviews are for the company's investigational therapies for the treatment of transthyretin (TTR) amyloidosis and achondroplasia.